AGEN vs. SGMO, CRIS, ATHA, DTIL, ALGS, NVAX, BCRX, FENC, MGX, and IVVD
Should you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Sangamo Therapeutics (SGMO), Curis (CRIS), Athira Pharma (ATHA), Precision BioSciences (DTIL), Aligos Therapeutics (ALGS), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Fennec Pharmaceuticals (FENC), Metagenomi (MGX), and Invivyd (IVVD). These companies are all part of the "biological products, except diagnostic" industry.
Sangamo Therapeutics (NASDAQ:SGMO) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations.
Agenus received 25 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 70.05% of users gave Agenus an outperform vote while only 62.66% of users gave Sangamo Therapeutics an outperform vote.
56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 2.8% of Sangamo Therapeutics shares are held by insiders. Comparatively, 4.8% of Agenus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Sangamo Therapeutics currently has a consensus price target of $5.67, indicating a potential upside of 942.05%. Agenus has a consensus price target of $130.00, indicating a potential upside of 887.84%. Given Agenus' higher possible upside, equities research analysts clearly believe Sangamo Therapeutics is more favorable than Agenus.
Sangamo Therapeutics has a net margin of -146.30% compared to Sangamo Therapeutics' net margin of -164.69%. Sangamo Therapeutics' return on equity of 0.00% beat Agenus' return on equity.
In the previous week, Agenus had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 5 mentions for Agenus and 4 mentions for Sangamo Therapeutics. Agenus' average media sentiment score of 0.23 beat Sangamo Therapeutics' score of 0.10 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
Sangamo Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.
Agenus has lower revenue, but higher earnings than Sangamo Therapeutics. Agenus is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Agenus beats Sangamo Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Agenus News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
